Critically ill patients frequently suffer from stress-induced hyperglycemia, glycemic variability or hypoglycemia which has been associated with increased morbidity and mortality in both diabetic and non-diabetic patients.

The OptiScanner 5000, which directly measures plasma glucose levels using an integrated blood centrifuge and spectrometer, delivers automated monitoring, no-calibration convenience and insights into trending data with the goal of avoiding dangerous glycemic variations and achieving the right level of glucose control.  Learn More

The OptiScanner 6000 will represent the first step of platform expansion, with the goal of providing hospitals and healthcare practitioners with a single source that detects both metabolic and hemodynamic analytes, all from the same sample of blood.

The OptiScanner 6000 will automatically measure and trend glucose, hemoglobin and central venous oxygen saturation levels to supply clinicians with early warning signs for critically ill patients at risk for sepsis, shock or bleeding. Learn More

CAUTION: In the U.S., the OptiScanner system is an investigational device limited by Federal (U.S.) law to investigational use. This investigational product has not been cleared or approved by the U.S. Food and Drug Administration for marketing in the United States. This investigational product is currently undergoing clinical study to verify its safety and effectiveness.

OptiScan Biomedical has received CE Mark certification for the OptiScanner 5000 system.